Blueprint
 
FORM 6-K
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
Report of Foreign Issuer
 
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 
For the month of April 2019
 
Commission File Number: 001-11960
 
AstraZeneca PLC
 
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F X Form 40-F __
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes __ No X
 
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
 
 
 
 
 
 
 
 
 
 
 
AstraZeneca PLC
 
INDEX TO EXHIBITS
 
 
1.
 Result of AGM
 
 
 
26 April 2019 17:45 BST
 
Results of Annual General Meeting held on 26 April 2019
 
AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 1 - 8 were passed as ordinary resolutions and resolutions 9 - 12 were passed as special resolutions.
 
 
RESOLUTION
 
VOTES FOR
 
% OF VOTES CAST
 
VOTES AGAINST
 
% OF VOTES CAST
 
VOTES CAST IN TOTAL
 
TOTAL VOTES CAST AS A % OF ISSUED SHARE CAPITAL
 
VOTES WITHHELD
 
1
 
To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2018
1,002,386,773
99.96
381,361
0.04
1,002,768,134
76.44%
2,130,013
2
To confirm dividends
1,000,878,921
99.65
3,545,943
0.35
1,004,424,864
76.57%
474,696
3
To reappoint PricewaterhouseCoopers LLP as Auditor
1,003,208,151
99.90
1,002,311
0.10
1,004,210,462
76.55%
688,850
4
To authorise the Directors to agree the remuneration of the Auditor
1,002,479,345
99.82
1,794,309
0.18
1,004,273,654
76.56%
625,255
5a
To re-elect Leif Johansson as a Director
998,953,618
99.51
4,884,897
0.49
1,003,838,515
76.53%
1,060,758
5b
To re-elect Pascal Soriot as a Director
1,001,460,120
99.73
2,740,412
0.27
1,004,200,532
76.55%
699,226
5c
To re-elect Marc Dunoyer as a Director
997,205,236
99.31
6,915,112
0.69
1,004,120,348
76.55%
775,679
5d
To re-elect Geneviève Berger as a Director
993,018,194
99.77
2,314,964
0.23
995,333,158
75.88%
9,563,029
5e
To re-elect Philip Broadley as a Director
995,659,475
99.16
8,475,542
0.84
1,004,135,017
76.55%
761,114
5f
To re-elect Graham Chipchase as a Director
958,824,389
97.22
27,400,052
2.78
986,224,441
75.18%
18,671,390
5g
To re-elect Deborah DiSanzo as a Director
1,001,808,208
99.77
2,336,040
0.23
1,004,144,248
76.55%
751,639
5h
To re-elect Sheri McCoy as a Director
1,000,164,666
99.60
3,984,489
0.40
1,004,149,155
76.55%
746,732
5i
To elect Tony Mok as a Director
1,003,431,827
99.93
699,122
0.07
1,004,130,949
76.55%
764,625
5j
To re-elect Nazneen Rahman as a Director
1,001,687,441
99.76
2,413,171
0.24
1,004,100,612
76.55%
795,505
5k
To re-elect Marcus Wallenberg as a Director
908,178,624
90.44
96,025,641
9.56
1,004,204,265
76.55%
691,663
6
To approve the Annual Report on Remuneration for the year ended 31 December 2018
947,606,599
95.86
40,895,170
4.14
988,501,769
75.36%
16,392,056
7
To authorise limited political donations
977,701,447
97.87
21,290,398
2.13
998,991,845
76.16%
5,895,452
8
To authorise the Directors to allot shares
877,861,679
87.43
126,178,566
12.57
1,004,040,245
76.54%
853,485
9
To authorise the Directors to disapply pre-emption rights
990,106,053
98.92
10,841,253
1.08
1,000,947,306
76.31%
3,944,848
10
To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments
979,272,055
97.83
21,681,201
2.17
1,000,953,256
76.31%
3,939,912
11
To authorise the Company to purchase its own shares
994,069,976
99.04
9,657,377
0.96
1,003,727,353
76.52%
1,164,722
12
To reduce the notice period for general meetings
905,789,402
90.67
93,205,859
9.33
998,995,261
76.16%
5,902,125
 
Issued capital
As at 24 April 2019, the number of issued shares of the Company was 1,311,759,192 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.
 
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in its main therapy areas - Oncology, CVRM and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.
 
Media Relations
 
 
Gonzalo Viña
UK/Global
+44 203 749 5916
Rob Skelding
UK/Global
+44 203 749 5821
Matt Kent
UK/Global
+44 203 749 5906
Jennifer Hursit
UK/Global
+44 203 749 5762
Christina M Hägerstrand
Sweden
+46 8 552 53 106
Michele Meixell
US
+1 302 885 2677
 
 
 
Investor Relations
 
 
Thomas Kudsk Larsen
 
+44 203 749 5712
Henry Wheeler
Oncology
+44 203 749 5797
Christer Gruvris
BioPharma - Cardiovascular; Metabolism
+44 203 749 5711
Nick Stone
BioPharma - Respiratory; Renal
+44 203 749 5716
Josie Afolabi
Other
+44 203 749 5631
Craig Marks
Finance; Fixed Income
+44 7881 615 764
Jennifer Kretzmann
Retail Investors; Corporate Access
+44 203 749 5824
US toll-free
 
+1 866 381 72 77
 
 
 
 
Adrian Kemp
Company Secretary
AstraZeneca PLC
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
AstraZeneca PLC
 
 
Date: 26 April 2019
 
 
By: /s/ Adrian Kemp
 
Name: Adrian Kemp
 
Title: Company Secretary